NO20082567L - Kombinasjon av ZD6474 og pemetrexed - Google Patents

Kombinasjon av ZD6474 og pemetrexed

Info

Publication number
NO20082567L
NO20082567L NO20082567A NO20082567A NO20082567L NO 20082567 L NO20082567 L NO 20082567L NO 20082567 A NO20082567 A NO 20082567A NO 20082567 A NO20082567 A NO 20082567A NO 20082567 L NO20082567 L NO 20082567L
Authority
NO
Norway
Prior art keywords
pemetrexed
human
combination
antiangiogenic
warm
Prior art date
Application number
NO20082567A
Other languages
English (en)
Inventor
Anderson Joseph Ryan
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526121A external-priority patent/GB0526121D0/en
Priority claimed from GB0610706A external-priority patent/GB0610706D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20082567L publication Critical patent/NO20082567L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for frembringelse av en anti-angiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt behandles med ioniserende stråling, særlig en fremgangsmåte for behandling av kreft, særlig kreft som involverer en fast tumor, som innbefatter administrasjon av ZD6474 i kombinasjon med pemetrexed; en farmasøytisk sammensetning som innbefatter ZD6474 og pemetrexed; et kombinasjonsprodukt som innbefatter ZD6474 og pemetrexed for anvendelse i en fremgangsmåte for behandling av menneske- eller dyrekroppen ved behandling, et kit som innbefatter ZD6474 og pemetrexed; anvendelsen av ZD6474 og pemetrexed for fremstilling av et medikament for anvendelse ved frembringelse av en anti-angiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt behandles med ioniserende stråling. 1
NO20082567A 2005-12-22 2008-06-02 Kombinasjon av ZD6474 og pemetrexed NO20082567L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526121A GB0526121D0 (en) 2005-12-22 2005-12-22 Combination therapy
GB0610706A GB0610706D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004750 WO2007071958A2 (en) 2005-12-22 2006-12-19 Combination of zd6474 and pemetrexed

Publications (1)

Publication Number Publication Date
NO20082567L true NO20082567L (no) 2008-07-31

Family

ID=37814151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082567A NO20082567L (no) 2005-12-22 2008-06-02 Kombinasjon av ZD6474 og pemetrexed

Country Status (19)

Country Link
US (2) US20080269261A1 (no)
EP (1) EP1971338B8 (no)
JP (1) JP5167144B2 (no)
KR (1) KR20080079675A (no)
AT (1) ATE500832T1 (no)
AU (1) AU2006328189B2 (no)
BR (1) BRPI0620140A2 (no)
CA (1) CA2631764A1 (no)
CY (1) CY1111547T1 (no)
DE (1) DE602006020621D1 (no)
DK (1) DK1971338T3 (no)
HR (1) HRP20110360T1 (no)
IL (1) IL191796A0 (no)
NO (1) NO20082567L (no)
NZ (1) NZ568811A (no)
PL (1) PL1971338T3 (no)
PT (1) PT1971338E (no)
SI (1) SI1971338T1 (no)
WO (1) WO2007071958A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
US20060167027A1 (en) * 2003-07-10 2006-07-27 Wedge Stephen R Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631676A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
CA2789895C (en) 2010-03-08 2019-04-09 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510991A (en) * 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US20050222183A1 (en) * 2002-08-09 2005-10-06 Wedge Stephen R Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
US20060167027A1 (en) * 2003-07-10 2006-07-27 Wedge Stephen R Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed
CA2631676A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
AU2006328189A1 (en) 2007-06-28
SI1971338T1 (sl) 2011-06-30
EP1971338B8 (en) 2011-09-21
US20110212978A1 (en) 2011-09-01
EP1971338A2 (en) 2008-09-24
JP5167144B2 (ja) 2013-03-21
US20080269261A1 (en) 2008-10-30
EP1971338B1 (en) 2011-03-09
HRP20110360T1 (hr) 2011-06-30
ATE500832T1 (de) 2011-03-15
BRPI0620140A2 (pt) 2011-11-01
CA2631764A1 (en) 2007-06-28
WO2007071958A2 (en) 2007-06-28
AU2006328189B2 (en) 2010-01-21
PT1971338E (pt) 2011-05-09
CY1111547T1 (el) 2015-08-05
WO2007071958A3 (en) 2008-03-27
DE602006020621D1 (de) 2011-04-21
JP2009520783A (ja) 2009-05-28
KR20080079675A (ko) 2008-09-01
PL1971338T3 (pl) 2011-07-29
HK1123186A1 (en) 2009-06-12
IL191796A0 (en) 2008-12-29
NZ568811A (en) 2011-06-30
DK1971338T3 (da) 2011-05-23

Similar Documents

Publication Publication Date Title
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
DK1653964T3 (da) Cancerkombinationsterapi omfattende AZD2171 og ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application